###begin article-title 0
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
'Self-Protection' of Individual CD4+ T Cells against R5 HIV-1 Infection by the Synthesis of Anti-Viral CCR5 Ligands
###end article-title 0
###begin p 1
Conceived and designed the experiments: YG RKL ALD GKL. Performed the experiments: YG. Analyzed the data: YG RKL ALD GKL. Contributed reagents/materials/analysis tools: YG SA. Wrote the paper: YG GKL.
###end p 1
###begin p 2
Current address: Department of Microbiology and Immunology, Faculty of Medicine, Minia University, Minia, Egypt
###end p 2
###begin p 3
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 90 91 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 215 216 215 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 441 442 441 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 495 496 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 654 655 654 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 722 723 722 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 973 974 973 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 184 189 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 244 249 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 359 364 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 611 616 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 779 784 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1000 1005 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
It is well established that paracrine secretion of anti-viral CCR5 ligands by CD8+ and CD4+ T cells can block the infection of activated CD4+ T cells by R5 and dual-tropic isolates of HIV-1. By contrast, because CD4+ T cells can be infected by HIV-1 and at least some subsets secrete anti-viral CCR5 ligands, it is possible that these ligands protect against HIV-1 via autocrine as well as paracrine pathways. Here we use a model primary CD4+ T cell response in vitro to show that individual CD4+ T cells that secrete anti-viral CCR5 ligands are 'self-protected' against infection with R5 but not X4 strains of HIV-1. This protection is selective for CD4+ T cells that secrete anti-viral CCR5 ligands in that activated CD4+ T cells in the same cultures remain infectable with R5 HIV-1. These data are most consistent with an autocrine pathway of protection in this system and indicate a previously unappreciated selective pressure on the emergence of viral variants and CD4+ T cell phenotypes during HIV-1 infection.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 202 210 195 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 212 215 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Cocchi1">[1]</xref>
###xml 232 235 225 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-DeVico1">[2]</xref>
###xml 402 405 395 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Paxton1">[3]</xref>
###xml 407 410 400 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Zagury1">[4]</xref>
###xml 434 437 427 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Wasik1">[5]</xref>
###xml 463 466 456 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-GarzinoDemo1">[6]</xref>
###xml 467 470 460 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Gonzalez2">[9]</xref>
###xml 517 518 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 598 599 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 637 641 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Huang1">[10]</xref>
###xml 725 726 718 719 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 887 890 880 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Paxton1">[3]</xref>
###xml 892 896 885 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Dragic1">[11]</xref>
###xml 897 901 890 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Paxton3">[13]</xref>
###xml 1055 1056 1048 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 341 346 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
It has been known for over a decade that CD8+ T cells secrete the anti-viral CCR5 ligands, CCL3 (MIP-1alpha), CCL4 (MIP-1beta), and CCL5 (RANTES), which block the infection of CCR5+ cells by R5 viruses in vitro ([1] and reviewed in [2]). Since then, a number of studies have implicated anti-viral CCR5 ligands in protective immunity against HIV-1 in the clinical settings of exposed uninfected cohorts [3], [4], neonatal transmission [5], and progression to AIDS [6]-[9]. Shortly after the original discovery that CD8+ T cells synthesize anti-viral CCR5 ligands a study appeared indicating that CD4+ T cells also secrete these molecules [10]. Several subsequent studies suggested that synthesis of CCR5 ligands by ex vivo CD4+ T cells correlates with resistance of these cells to infection and indicated an inverse relationship between CCR5 ligand synthesis and lower co-receptor levels [3], [11]-[13]. These studies did not place CCR5 ligand synthesis into a precise immunological context defined by the response phase (i.e., primary or secondary) or CD4+ T cell subsets synthesizing the ligands.
###end p 5
###begin p 6
###xml 23 27 23 27 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-KaminLewis1">[14]</xref>
###xml 29 33 29 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Sun1">[15]</xref>
###xml 46 50 46 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-DeRosa1">[16]</xref>
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Casazza1">[17]</xref>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-KaminLewis1">[14]</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-DeRosa1">[16]</xref>
###xml 384 385 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 699 700 699 700 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
To this end, our group [14], [15] and another [16], [17] reported the synthesis of a CCR5 ligand, CCL4, by memory CD4+ T cell subsets in uninfected volunteers. Interestingly, the frequencies of memory CD4+ T cells that synthesize CCL4 in response to antigenic stimulation were substantially lower than those found for CD8+ T cells [14], [16]. Collectively, these studies show that CD4+ T cells can synthesize anti-viral CCR5 ligands during the memory phase of an adaptive immune response, although CD8+ T cell subsets might be the predominant source of these molecules at this point in the adaptive immune response. Less is known about the synthesis of anti-viral CCL5 ligands during the primary CD4+ T cell response.
###end p 6
###begin p 7
###xml 41 49 41 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 91 92 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 290 298 290 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 613 621 613 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 790 791 790 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 159 165 <span type="species:ncbi:9606">people</span>
###xml 572 577 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 817 822 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To address this issue, we established an in vitro model of the primary antigen specific CD4+ T cell response in which purified naive CD4+ T cells from healthy people are co-cultured with monocyte derived dendritic cells (MDDC) plus antigen [18]. The subsequent immune response was measured in vitro by activation parameters including the synthesis of anti-viral CCR5 ligands [18]. In this report, we extend those studies by showing that individual CD4+ T cells which synthesize anti-viral CCR5 ligands are 'self-protected' against infection with R5 but not X4 isolates of HIV-1 during the primary immune response in vitro. These data are most consistent with an autocrine mode of protection and indicate previously unappreciated selective pressure on the emergence of viral variants and CD4+ T cell phenotypes during HIV-1 infection.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
Reagents
###end title 9
###begin p 10
###xml 502 506 <span type="species:ncbi:11676?0.7906976744186046">HIV1</span>
###xml 596 600 <span type="species:ncbi:9925">goat</span>
###xml 665 669 <span type="species:ncbi:9925">goat</span>
###xml 716 730 <span type="species:ncbi:1280">Staphylococcus</span>
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque(R) centrifugation using blood obtained from normal healthy volunteers either through commercial sources or by venipuncture of healthy adult volunteers under approval of the University of Maryland Institutional Review Board or through commercial sources. The following fluorochrome-labeled antibodies were purchased from BD Biosciences (San Jose, CA): CD4-FITC, CD3-PerCP, CD45RO-APC, CD86-PE and CCL4-PE. The antibodies against HIV1 p24 (KC57-RD and KC57-FITC) were obtained from Beckman Coulter (Miami, FL). Neutralizing goat antibodies specific for CCL3, CCL4, and CCL5, along with normal goat IgG, were from R&D Systems (Minneapolis, MN). Staphylococcus enterotoxin B (SEB) was purchased from Sigma (St. Louis, MO).
###end p 10
###begin title 11
Preparation of Virus Stocks
###end title 11
###begin p 12
###xml 36 40 36 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 47 54 47 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92BR020</sub>
###xml 61 67 61 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Jv1083</sub>
###xml 74 79 74 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF162</sub>
###xml 107 111 107 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">89.6</sub>
###xml 118 125 118 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92HT594</sub>
###xml 136 141 136 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BZ167</sub>
###xml 165 172 165 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">92ug024</sub>
###xml 179 182 179 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lai</sub>
###xml 189 193 189 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIIB</sub>
###xml 200 204 200 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2044</sub>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 31 34 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 42 45 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 56 59 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 69 72 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 102 105 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 113 116 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 131 134 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 160 163 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 174 177 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 184 187 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 195 198 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 508 513 <span type="species:ncbi:9606">Human</span>
HIV-1 stocks (four R5 viruses: HIV-1Ba-L, HIV-192BR020, HIV-1Jv1083, HIV-1SF162; three R5/X4 viruses: HIV-189.6, HIV-192HT594, and HIV-1BZ167; four X4 viruses: HIV-192ug024, HIV-1Lai, HIV-1IIIB, HIV-12044) were obtained originally from the NIAID AIDS Reference and Research Reagent Repository (Kensington, MD). Working viral stocks were prepared for this study by infection of CD8-depleted PHA-stimulated PBMCs from a single donor using seed stocks maintained in the uQuant Core Facility at the Institute of Human Virology.
###end p 12
###begin title 13
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 53 61 53 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Viral Infection During Primary CD4+ T Cell Responses in vitro
###end title 13
###begin p 14
###xml 109 117 109 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 240 241 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 703 704 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 761 765 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 872 873 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 895 896 895 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1126 1127 1122 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1173 1174 1169 1170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1248 1249 1244 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 817 822 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1284 1289 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1554 1559 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Generation of immature monocyte-derived dendritic cells (MDDC) and the culture system for generating primary in vitro CD4+ T cell responses were described in detail previously [18]. In this system, highly enriched naive (CD45RO- CD62L+) CD4+ T cells are cultured with autologous MDDC and nominal antigen, allogeneic MDDC (as alloantigen), or superantigens for periods of up to three weeks. Responses are monitored by cell division by CFSE dilution and for changes in phenotype and function by surface markers and cytokine production, respectively. Responses in this system are strictly dependent upon MDDC as antigen presenting cells and foreign antigen. The ability of this system to detect primary CD4+ T cell responses in a clonal fashion has been described [18]. For viral infection, 1000 TCID50 of the indicated HIV-1 isolates were added with naive CD4+ T cells (2x105 per well), MDDC (2x103 per well) and antigen (100 ng/ml SEB) in 200 microl per well medium in U-bottom 96-well plates. In some experiments, alloantigens were used in lieu of SEB to elicit the primary immune response. This was accomplished by using 1x104 allogeneic MDDC as the stimulus for naive CD4+ T cells. Viral infection of MDDC was performed by co-culturing MDDC (2x104 per well) with 1000 TCID50 of the HIV-1 isolates as indicated in the text. Aliquots of supernatants were removed on days 2, 5, 8, 11, and 14 and quantified for p24 concentrations by ELISA (New England Nuclear, Cambridge, MA). Alternatively, viral replication was determined by intracellular staining for HIV-1 p24 antigen as described below. Each experiment was repeated at least twice with comparable results.
###end p 14
###begin title 15
Intracellular staining
###end title 15
###begin p 16
###xml 650 654 <span type="species:ncbi:11676?0.7906976744186046">HIV1</span>
###xml 812 817 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cells were collected at the time points indicated in the Results section and washed twice in staining buffer [PBS with 2% BSA and 0.1% Sodium azide]. They were stained for surface markers as indicated in the Results section, fixed, and permeabilized for intracellular staining according to manufacturer's instructions using the Cytofix/Cytoperm Plus kit (BD Biosciences, San Jose, CA). For detection of intracellular MIP1beta, Golgistop reagent (BD Biosciences, San Jose, CA) was added on day 6 for the last 10 hours of culture before collecting cells for staining as described above. We used the KC57-FITC antibody for detection of intracellular of HIV1 p24 antigen and MIP1beta-PE antibody for detection of intracellular CCL4. Experience has shown that it is difficult to reliably detect the two other anti-R5 HIV-1 beta-chemokines, CCL3 and CCL5 by intracellular staining. For this reason we were only able to follow the synthesis of CCL4 (MIP-1beta). Co-staining for p24 and CCL4 was carried out after the last 10 hours of culture in the presence of Golgistop. Data were acquired by six-parameter flow cytometry and analyzed with FlowJo software (Treestar, Inc., San Carlos, CA).
###end p 16
###begin title 17
Results
###end title 17
###begin title 18
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 38 43 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Selective replication of X4 and R5/X4 HIV-1 during the in vitro primary CD4+ T cell response
###end title 18
###begin p 19
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 99 107 99 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 230 234 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Bagley1">[19]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Bagley3">[21]</xref>
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Buonaguro1">[22]</xref>
###xml 418 427 418 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1a</xref>
###xml 444 465 444 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 479 488 479 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1a</xref>
###xml 591 595 591 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">89.6</sub>
###xml 721 726 721 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF162</sub>
###xml 1002 1011 1002 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1b</xref>
###xml 1272 1273 1270 1271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1290 1298 1288 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 317 322 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 394 399 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 586 589 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 716 719 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The ability of R5, X4, and R5/X4 isolates of HIV-1 to replicate in CD4+ T cells during the primary in vitro immune response was determined using a system developed by our group to evaluate the synthesis of anti-viral CCR5 ligands [18], the effects of adjuvants on antigen presentation [19]-[21], and the responses to HIV-1 vaccine candidates [22]. Cultures were initiated and infected with the HIV-1 isolates shown in Figure 1a as described in Materials and Methods. As shown in Figure 1a, five of the six X4 and R5/X4 viruses replicated by day 8 of the culture period. The R5/X4 virus HIV-189.6 replicated poorly, if at all. By contrast, none of the four R5 viruses replicated early in the culture period with only HIV-1SF162 showing a modest increase in p24 by day 11. Since the differences in replication appeared to be greatest during the first 11 days of culture, we compared the day 8 median p24 concentrations of the three groups for statistical significance using Student's t-test. As shown in Figure 1b, the differences between the R5 group and either the X4 or X4/R5 groups were statistically significant (p = 0.02) for X4 viruses, p</=0.05 for X4/R5 viruses). These data show that X4 and X4/R5 viruses selectively replicate during the antigen driven primary CD4+ T cell response in vitro with little or no replication of R5 viruses under these experimental conditions. This conclusion was confirmed in subsequent experiments by analysis of intracellular p24.
###end p 19
###begin title 20
###xml 64 72 64 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Selective replication of X4 or R5/X4 viruses during the primary in vitro CD4+ T cell response to SEB.
###end title 20
###begin p 21
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 233 241 233 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 258 279 258 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 713 714 713 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 721 722 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 970 971 970 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1126 1147 1126 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 1182 1183 1182 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1190 1191 1190 1191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1403 1404 1403 1404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1500 1509 1500 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1a</xref>
###xml 374 378 <span type="species:ncbi:11676?0.7906976744186046">HIV1</span>
###xml 1021 1026 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
a. Four R5 viruses (Ba-L, 92BR020, Jv1083, SF162), three R5/X4 viruses (89.6, 92HT594, BZ167) and three X4 viruses (92ug024, Lai, IIIB) were added along with naive CD4+ T cells plus MDDC and SEB to initiate a primary immune response in vitro as described in Materials and Methods. The viral input was 1000 TCID50 per culture. Viral replication was monitored by detection of HIV1 p24 antigen in supernatant and shown in red for R5 viruses, magenta for R5/X4 viruses, and blue for X4 viruses. b. Day 8 p24 levels were pooled for each viral co-receptor family and the medians were compared for statistical significance by a double tailed Student's t-test. c. Representative examples are shown of p24 staining for CD4+ CD45RO+ T cells responding to SEB and autologous MDDC in the presence of a R5 virus (Ba-L), a R5/X4 virus (BZ167), or a X4 virus (IIIB), the latter in the presence and absence of AZT ( 10 uM). Cells were harvested on day 7 post-initiation of a primary CD4+ T cell response in the presence of the indicated HIV-1 isolates (1000 TCID50 per culture) and stained for surface markers and p24 antigen as described in Materials and Methods. d. Median frequencies of p24+ CD4+ CD45RO+ cells were pooled for each co-receptor family and compared for statistical significance by a two-tailed Student's t-test. The data are from staining analyses carried out on day 7 cells generated in a primary CD4+ T cell response to SEB in the presence of 1000 TCID50 of the R5, R5/X4, and X4 viruses used in Figure 1a.
###end p 21
###begin p 22
###xml 47 63 47 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1c and 1d</xref>
###xml 139 148 139 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1a</xref>
###xml 206 227 206 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 229 238 229 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1c</xref>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 367 371 367 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 395 400 395 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BZ167</sub>
###xml 424 428 424 428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIIB</sub>
###xml 490 494 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 496 500 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Buonaguro1">[22]</xref>
###xml 551 560 551 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1a</xref>
###xml 631 635 631 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 714 723 714 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1c</xref>
###xml 1139 1148 1139 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1a</xref>
###xml 1177 1178 1177 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1185 1186 1185 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1260 1269 1260 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1d</xref>
###xml 1298 1299 1298 1299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1306 1307 1306 1307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1311 1312 1311 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1754 1755 1754 1755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1870 1871 1870 1871 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2189 2197 2189 2197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g002">Figure 2</xref>
###xml 362 365 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 390 393 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 419 422 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 626 629 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The data from one such experiment are shown in Figure 1c and 1d where cells were harvested on day 7 from cultures established as above for Figure 1a washed and stained for intracellular p24 as described in Materials and Methods. Figure 1c shows typical intracellular staining of CD4+ CD45RO+ T cells for intracellular p24 for cultures infected with an R5 virus (HIV-1Ba-L), an R5/X4 virus (HIV-1BZ167), or an X4 virus (HIV-1IIIB). Note that CD45RO marks responding cells in our assay system[18], [22]. As expected from the results on supernatant p24 (Figure 1a), no p24 staining was found for cultures infected with R5 virus, HIV-1Ba-L, whereas p24 staining was apparent for both the R5/X4 and X4 viruses shown in Figure 1c. Staining for p24 was absent when an inhibitory concentration AZT was included in a parallel culture exposed to the X4 virus, showing that the observed staining required active reverse transcription and that the p24 signal was not due to passively adsorbed protein from the input virus. Statistical significance of differential infection as determined by p24 staining was assessed for the same virus panel shown in Figure 1a using the frequencies of CD4+ CD45RO+ T cells that also express p24. The results of this analysis are shown in Figure 1d where the frequencies of CD4+ CD45RO+ p24+ cells in R5 cultures were approximately 100-fold lower than those observed for the R5/X4 and X4 virus panels. These differences were statistically significant as determined by a two-tailed Student's t-test (p = 0.044 and p = 0.001 for comparisons of the R5 viruses with the R5/X4 and X4 viruses, respectively). These data confirm the conclusions reached using p24 supernatant concentrations as the readout and show that antigen activated CD4+ T cells are the probable source of the virus. As the cultures were initiated with both immature MDDC and naive CD4+ T cells, we cannot formally rule out a contribution of the MDDC to the virus found in the supernatants. However, this is unlikely given the small number of MDDC in the cultures (1% at culture initiation) and by additional studies in which R5 viruses selectively replicate in cultures of immature MDDC cultured alone (Figure 2). Thus, it is unlikely that MDDC infection accounts for our results.
###end p 22
###begin title 23
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Selective replication of R5 HIV-1 in immature MDDC.
###end title 23
###begin p 24
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 136 143 136 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Methods</xref>
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 230 235 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Immature MDDC cells ( 2x104 per well) were cultured with 1000 TCID50 of the HIV-1 viruses indicated in the figure panel as described in Methods. Supernatants were collected on days 2, 5, 8, 11 and 14 post-infection and tested for HIV-1 p24 antigen by ELISA. The results are shown in red for R5 viruses, magenta for R5/X4 viruses, and blue for X4 viruses.
###end p 24
###begin title 25
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 111 119 111 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 65 70 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Antibodies to antiviral CCR5 ligands allow the replication of R5 HIV-1 during the primary CD4+ T cell response in vitro
###end title 25
###begin p 26
###xml 165 166 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 243 251 243 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1</xref>
###xml 263 267 263 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 488 497 488 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g003">Figure 3a</xref>
###xml 513 517 513 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 530 534 530 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 570 574 570 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 635 642 632 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g003">Fig. 3a</xref>
###xml 735 739 732 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 748 752 745 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 779 788 776 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g003">Figure 3a</xref>
###xml 904 908 901 905 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 1054 1055 1048 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1062 1063 1056 1057 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1079 1088 1073 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g003">Figure 3b</xref>
###xml 1370 1371 1361 1362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1388 1396 1379 1387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1584 1585 1575 1576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 258 261 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 407 411 <span type="species:ncbi:9925">goat</span>
###xml 508 511 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 525 528 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 551 555 <span type="species:ncbi:9925">goat</span>
###xml 565 568 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 604 608 <span type="species:ncbi:9925">goat</span>
###xml 730 733 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 743 746 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 769 773 <span type="species:ncbi:9925">goat</span>
###xml 899 902 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 929 933 <span type="species:ncbi:9925">goat</span>
###xml 1221 1225 <span type="species:ncbi:9925">goat</span>
###xml 1675 1680 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The poor replication of R5 viruses in the experiments described above strongly suggested that the effect is due to anti-viral CCR5 ligands made by the responding CD4+ T cells. To test this hypothesis, cultures were established as described in Figure 1 using HIV-1Ba-L as the R5 virus but spiked with a mixture saturating concentrations of blocking antibodies specific for CCL3, CCL4, and CCL5 or non-immune goat IgG as the negative control. The experimental groups (shown in duplicate in Figure 3a ) include HIV-1Ba-L alone, HIV-1Ba-L with non-immune goat IgG, and HIV-1Ba-L with the mixture of blocking goat anti-beta-chemokine IgGs (Fig. 3a, black lines). As expected, no viral replication was observed for groups cultured with HIV-1Ba-L or HIV-1Ba-L plus non-immune goat IgG (Figure 3a, red and magenta lines, respectively). By contrast, viral replication was observed in the group cultured with HIV-1Ba-L plus the mixture of goat anti-beta-chemokine IgGs. Intracellular p24 staining confirmed the presence of viral protein synthesis in responding CD4+ CD45RO+ T cell blasts (Figure 3b) in the cultures treated with the mixture of anti-beta-chemokine IgGs (right panel) but not in the cultures treated with non-immune goat IgG (middle panel). These results support the hypothesis that the anti-viral CCR5 ligands, CCL3, CCL4, and CCL5, produced during the primary CD4+ T cell response in vitro are sufficient to severely dampen replication of an R5 virus present continuously in the culture. They also set the stage in this culture system for determining whether the individual CD4+ T cells that secrete anti-viral CCR5 ligands are 'self-protected' from infection with R5 HIV-1.
###end p 26
###begin title 27
###xml 88 96 85 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 112 113 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Anti-beta-chemokine antibodies reverse the block to R5 HIV-1 replication in the primary in vitro response of CD4+ T cells to SEB.
###end title 27
###begin p 28
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 204 208 204 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 586 595 586 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1c</xref>
###xml 631 635 631 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ba-L</sub>
###xml 796 805 793 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g003">Figure 3a</xref>
###xml 3 7 <span type="species:ncbi:9925">Goat</span>
###xml 199 202 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 388 392 <span type="species:ncbi:9925">goat</span>
###xml 626 629 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
a. Goat antibodies to CCL3, CCL4, and CCL5 were added at 25 ug/ml (final concentration of each antibody) to cultures of naive CD4+ T cells and autologous MDDC plus SEB in the presence of 1000 TCID50 HIV-1Ba-L and viral replication monitored on the indicated days by p24 ELISA. Controls included cultures initiated in the absence of exogenous antibodies and cultures initiated with normal goat IgG (75 ug/ml final concentration). Supernatant p24 concentrations are shown for duplicate cultures. b. Bivariate histograms for p24 versus CD45RO were generated as described in the legend for Figure 1c to confirm the replication of HIV-1Ba-L in the presence of saturating concentrations of ant-beta-chemokine antibodies. The data are shown for a day 7 culture established as described in the legend to Figure 3a.
###end p 28
###begin title 29
###xml 96 104 96 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 146 151 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Individual CD4+ T cells that secrete anti-viral CCR5 ligands during the primary immune response in vitro are 'self-protected' from concomitant R5 HIV-1 infection
###end title 29
###begin p 30
###xml 861 869 858 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g004">Figure 4</xref>
###xml 924 932 921 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1</xref>
###xml 1254 1259 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The above results suggest that the individual CD4+ T cells that secrete anti-viral CCR5 ligands might be selectively protected from infection by R5 viruses. This 'self-protection' hypothesis predicts that the synthesis of anti-viral CCR5 ligands and viral proteins at the single cell level should tend toward mutual exclusivity for R5 viruses but not for X4 viruses in our culture system. Since we have to add blocking anti-beta chemokine antibodies to establish infections with R5 viruses in the SEB stimulated cultures; it is difficult to test this hypothesis using this potent antigen as the readout. In preliminary studies, we found that using weaker antigenic stimuli, such as allogeneic MDDC, permits modest replication of R5 viruses, which allowed us to test the hypothesis in the absence of blocking anti- beta -chemokine antibodies. The study shown in Figure 4 was carried out essentially the same as that shown in Figure 1 except that allogeneic MDDC were used in lieu of SEB and autologous MDDC as antigen to elicit the primary CD4+ T cell response. Single cell analyses were carried out on day 7 of culture by intracellular staining and flow cytometry using fluorescent monoclonal antibodies to CCL4 and p24 as markers for beta-chemokine and HIV-1 infection, respectively.
###end p 30
###begin title 31
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Exclusive expression of p24 and CCL4 in CD4+ T cells undergoing a primary immune response in the presence of R5 but not X4 HIV-1-.
###end title 31
###begin p 32
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 206 227 206 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 356 365 356 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g004">Figure 4a</xref>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 446 451 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
a. Naive CD4+ T cells were cultured with allogeneic MDDC in the presence of 1000 TCID50 of the HIV-1 isolates indicated in the figure and intracellular p24 and CCL4 staining was carried out as described in Materials and Methods on cultures harvested at day 7. b. Ratios of CCL4+ p24+ cells to CCL4+ p24- cells were calculated for each virus shown in panel Figure 4a and the medians used to determine statistical significance between the R5 an X4 HIV-1 groups using a two-tailed Student's t-test.
###end p 32
###begin p 33
###xml 12 21 12 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g004">Figure 4a</xref>
###xml 376 377 376 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 396 397 396 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 498 507 498 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g004">Figure 4b</xref>
###xml 526 527 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 531 532 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 546 547 546 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 551 552 551 552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 659 660 657 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 664 665 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 679 680 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 684 685 682 683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 766 775 764 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g004">Figure 4b</xref>
###xml 1124 1132 1120 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1224 1225 1220 1221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
As shown in Figure 4a, there was less apparent coincident staining for CCL4 and p24 in cultures infected with R5 viruses (upper panel) as compared with X4 viruses (lower panel). R5/X4 viruses were not evaluated in this series of studies. The apparent differences in coincident CCL4 and p24 staining were evaluated for statistical significance by calculating the ratios of CCL4+ p24- cells to CCL4+ p24+ cells for the R5 and X4 virus panel and analysis by a two-tailed Student's t-test. As shown in Figure 4b, the ratio of CCL4+ p24- cells to CCL4+ p24+ cells ranged from 8.08 to 54.17 (mean = 27.71+/-19.24 (SD)) for R5 viruses. By contrast, the ratio of CCL4+ p24- cells to CCL4+ p24+ cells was approximately 10-fold less for X4 viruses, ranging from 0.97 to 5.65 (Figure 4b, mean = 2.73+/-2.07 (SD)). This difference was statistically significant (p = 0.04) indicating a greater degree of co-incident staining between p24 and CCL4 for the X4 viruses as compared to the R5 viruses. Taken together, these data support the hypothesis that CD4+ T cells which secrete anti-viral CCR5 ligands during the primary immune response in vitro are selectively protected from infection by R5 viruses as compared with other activated CD4+ T cells in the same culture that do not secrete these ligands. These data are most consistent with an autocrine pathway of protection.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 294 302 294 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 472 473 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 705 706 705 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 940 941 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 163 168 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 227 232 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 521 526 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 648 653 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 883 888 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The principal conclusion of this report is that CD4+ T cells which secrete anti-viral CCR5 ligands during the primary immune response are 'self-protected' from R5 HIV-1 infection. This conclusion is based on kinetic studies of HIV-1 replication during the primary antigen specific CD4+ T cells in vitro where R5 virus growth was selectively dampened by the synthesis of anti-viral CCR5 ligands by the responding T cells. It is also based on single cell analyses of the CD4+ T cells undergoing a primary response where R5 HIV-1 infection and the synthesis of CCL4 were largely exclusive. By contrast, significant exclusivity was not observed for X4 HIV-1 infection. Taken together, these data show that CD4+ T cells, which synthesize anti-viral CCR5 ligands during the primary immune response, are "self-protected". To our knowledge, this is a new phenomenon in the interplay between HIV-1 infection and anti-viral effector mechanisms of CD4+ T cells, which are the principal targets of this virus. Four aspects of this observation warrant further discussion.
###end p 35
###begin p 36
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 142 149 142 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 189 190 189 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 246 249 246 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Cocchi1">[1]</xref>
###xml 251 254 251 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Cocchi2">[7]</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-KaminLewis1">[14]</xref>
###xml 400 401 400 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 568 569 568 569 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 629 630 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 641 642 641 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Riley1">[23]</xref>
###xml 779 780 779 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 931 932 931 932 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1107 1108 1107 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1157 1158 1157 1158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1309 1313 1309 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Roederer1">[24]</xref>
###xml 1372 1373 1372 1373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1380 1381 1380 1381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1387 1388 1387 1388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1415 1416 1415 1416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1441 1442 1441 1442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1510 1511 1510 1511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 81 86 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 308 311 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
First, this observation strongly suggests that CD4+ T cells manifest potent anti-HIV-1 effector activity early in the primary immune response in vivo. It is well established that memory CD8+ T cells secrete high levels of anti-viral CCR5 ligands [1], [7], [14] constituting one of several cell-mediated anti-HIV effector mechanisms; however, less is known about the production of these factors by CD4+ T cell subsets during the different phases (i.e., primary and secondary) of an immune response. In an early study using CD45RA and CD45RO to mark naive and memory CD4+ T cell subsets, respectively, it was shown that both CD45RA+ and CD45RO+ subsets activated by anti-CD3 plus anti-CD28 secreted anti-viral CCR5 ligands [23]. Our results showing that antigen-activated naive CD4+ T cells secrete anti-viral CCR5 ligands agree and extend those studies. They agree in that both sets of studies show that recently activated naive CD4+ T cells secrete anti-viral CCR5 ligands. Our studies place this observation on a more solid footing in that the previous study used only CD45RA expression to define naive CD4+ T cells. It is known that a subset of memory CD4+ T cells in normal individuals also express CD45RA and that a second marker, such as CD62L needs to be used to exclude this subset from the naive pool [24]. In the above experiments, naive cells were defined as CD4+ CD45RO- CD62L+, which excludes the CD45RA+ population of memory CD4+ T cells. Because of this, our studies more precisely define the CD4+ T cell subsets that secreted anti-viral CCR5 ligands.
###end p 36
###begin p 37
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 136 137 136 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 166 167 166 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-KaminLewis1">[14]</xref>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-DeRosa1">[16]</xref>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 278 279 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-KaminLewis1">[14]</xref>
###xml 375 383 375 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 414 415 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 609 610 609 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 615 616 615 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 633 637 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 662 663 662 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Using this marker strategy we showed previously that that CCL4 is made by CD8+ and CD4+ memory T cells where greater frequencies of CCL4+ cells were found for the CD8+ subsets [14]. This has been confirmed by others during vaccine evaluation [16]. By contrast, naive CD4+ or CD4+ T cells did not synthesize CCL4 in short term assays [14]. However, shortly after immunization in vitro with model antigens, naive CD4+ T cells differentiate into blasts that secrete CCL3, CCL4, and CCL5 at levels that are potently anti-viral when culture supernatants are evaluated in trans using R5 viruses and assays using CD4+ CCR5+ indicator cells [18]. This indicated that CD4+ T cells could exert potent anti-viral activity early in the primary immune response.
###end p 37
###begin p 38
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 203 210 203 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 341 342 341 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 537 538 537 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 545 546 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 747 752 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 880 885 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1170 1175 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1323 1328 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1366 1371 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
This observation led us to the current studies where we directly challenged antigen-driven primary CD4+ T cell responses with R5, R5/X4, and X4 viruses to determine whether these CCR5 ligands are active in situ. In the studies described above, the viruses were simply added at the time of culture initiation with antigen, MDDC, and naive CD4+ T cells and viral growth monitored over the course of the primary response. In all cases, strong primary immune responses were observed to the model antigens as judged by high frequencies of CD4+ CD45RO+ T cells in the stimulated cultures. It should be noted that CD45RO expression is upregulated within hours after antigen stimulation in our culture system ([18] and unpublished). Thus, the presence of HIV-1 during this early phase of the immune response is not suppressive. We used SEB and alloantigens as the immunogens because anti-HIV-1 primary responses are small in magnitude in our system and these responses are highly reproducible among volunteers (unpublished). In addition, the primary alloantigen response provided a fortuitously optimal dynamic range of response for the bivariate analyses of CCL4 synthesis and HIV-1 infection monitored by intracellular CCL4 and p24 expression. This raises one caveat in that our conclusions are based on primary responses to non-HIV-1 antigens, although it is likely that HIV-1 specific T cells are among the spectrum of responding T cells elicited by SEB and alloantigens.
###end p 38
###begin p 39
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Criado1">[25]</xref>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Bueno1">[26]</xref>
###xml 455 456 455 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
There is another potential caveat in using superantigens as opposed to peptide-MHC complexes (i.e., alloantigens or nominal protein antigens) in that superantigens activated CD4+ T cells through both lck-dependent and lck-independent pathways whereas peptide-MHC complexes apparently stimulate only via the former pathway [25], [26]. In this regard, it is important to note that the key observation in the studies described above, 'self-protection' of CD4+ T cells by the synthesis anti-viral CCR5 ligands, was made using alloantigen (i.e., peptide-MHC) stimulation. This tempers the caveat that the lck-independent pathway contributes to this observation.
###end p 39
###begin p 40
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 442 446 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Selin1">[27]</xref>
###xml 790 794 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Douek1">[28]</xref>
###xml 796 800 796 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Roederer2">[29]</xref>
###xml 929 933 929 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Moore1">[30]</xref>
###xml 934 938 934 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Sabbe1">[32]</xref>
###xml 1062 1063 1062 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 201 204 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 698 703 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Second, the selective pressure exerted by anti-viral CCR5 ligands secreted by CD4+ T cells undergoing a primary immune response could affect both the viral and cellular phenotypes that emerge early in HIV infection. Immune responses to different viruses can result in distinct populations of memory T cells that differ not only in the spectrum of their antigen receptor sequences but also surface phenotype and effector function (reviewed in [27]). This is due to the local ecology of the cell types infected by the virus and by adaptation of the responding T cells to effectively confront the virus, which attempts to escape the response by evolution under this selective pressure. In the case of HIV-1, it has been known for some time that distinct T cell subsets emerge during infection [28], [29] and that this is often paralleled by the emergence of viral variants with distinct phenotypes such as altered co-receptor usage [30]-[32], although the two phenomena have not been causally linked by direct experiment. Our studies suggest a mechanism whereby CD4+ T cell phenotype can affect viral phenotype and vice versa during a primary immune response.
###end p 40
###begin p 41
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 370 371 370 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 473 474 473 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Douek2">[33]</xref>
###xml 786 787 786 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 948 949 948 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1092 1093 1092 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1100 1101 1100 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1106 1107 1106 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1112 1113 1112 1113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1188 1192 1188 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-OswaldRichter1">[34]</xref>
###xml 1283 1284 1283 1284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 164 169 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 345 350 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 450 453 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 507 512 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 635 640 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 688 693 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 768 773 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 923 928 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1144 1150 <span type="species:ncbi:9606">people</span>
###xml 1172 1177 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Since our results show that CD4+ T cells secreting anti-viral CCR5 ligands during the primary immune response are selectively protected from R5 but not X4 viruses, HIV-1 specific CD4+ T cells with this phenotype should selectively survive during acute infection and contribute ultimately to the memory pool. It is interesting to note that while HIV-1 specific memory CD4+ T cells are selectively infected during an ongoing infection as compared with CMV specific memory CD4+ T cells, only a fraction of the HIV-1 specific memory cells are infected [33]. While it is possible that this result simply represents the stochastic nature of HIV-1 infection, it is striking that the majority of HIV-1 specific cells were not infected. Our studies suggest that the uninfected HIV-1 specific CD4+ T cells might be refractory to infection because they produce anti-viral CCR5 ligands and are 'self-protected'. If so, we predict that HIV-1 specific memory CD4+ T cells that survive during infection secrete anti-viral CCR5 ligands. In this vein, a recent report described the emergence of an unusual CD4+ CD45RA+ CCR7- CCR5+ memory population in infected people that is resistant to HIV-1 infection [34]. It will be interesting to learn whether these memory cells derive from the lineage of CD4+ T cells that secrete anti-viral CCR5 ligands during the primary immune response.
###end p 41
###begin p 42
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Chun1">[35]</xref>
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Chun2">[36]</xref>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 301 305 301 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Chun3">[37]</xref>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Finzi1">[38]</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Finzi2">[39]</xref>
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Pierson1">[40]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Finzi2">[39]</xref>
###xml 464 468 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Pierson1">[40]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Pierson2">[41]</xref>
###xml 256 261 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 799 804 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Third, it is possible that the synthesis of anti-viral CCR5 ligands early in the primary immune response contributes a selective pressure to generate the latent viral reservoir in resting CD4+ T cells [35], [36]. The CD4+ T cell reservoir latent harboring HIV-1 is established very early in infection [37], [38] and it persists throughout the course of infection [39], [40] with apparent replenishment even in individuals undergoing successful HAART therapy [39], [40]. Furthermore, this latent pool is populated predominantly by R5 viruses [41]. Viral latency is one means to escape selective pressure and it is tempting to speculate that the selective pressure exerted by anti-viral CCR5 ligands early in the primary immune response contributes to the early establishment of the latent pool of R5 HIV-1. This hypothesis is currently under investigation using our system.
###end p 42
###begin p 43
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Mosier1">[42]</xref>
###xml 298 305 298 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 532 537 532 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF162</sub>
###xml 539 548 539 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003481-g001">Figure 1a</xref>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Mosier1">[42]</xref>
###xml 930 935 930 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SF162</sub>
###xml 1117 1118 1117 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1135 1143 1135 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1143 1147 1143 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Abdelwahab1">[18]</xref>
###xml 1196 1197 1196 1197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 342 347 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 527 530 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 925 928 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Fourth, our studies also suggest a mechanism that could drive the co-receptor switch early in infection. It is well established that the co-receptor switch can occur rapidly in scid-Hu mice under the selective pressure of CCL5 [42] and it is reasonable to suspect that a similar switch could occur in vivo under pressure of CCL5 synthesis by HIV-1 specific CD4+ T cells undergoing a primary immune response. We are testing this hypothesis in our system where delayed viral growth is observed for some R5 virus isolates such as HIV-1SF162 (Figure 1a). This virus might be particularly susceptible to co-receptor switching as it has been shown that it has a single pathway to X4 usage that is determined by two common mutations in the V3 loop (I309R and A316V) regardless of whether the selection pressure was exerted by culturing in the presence of CCL5 or by switching cellular substrates [42]. Thus, it is possible that the HIV-1SF162 that appears late in our culture system is actually co-receptor switched. We are testing this hypothesis but the potent secretion of anti-viral CCL5 ligands in the early primary CD4+ T cell response in vitro[18] coupled with the selective protection of the CD4+ T cells that synthesize these ligands, strongly suggests a role for anti-viral chemokines in protection against R5 viruses early in infection.
###end p 43
###begin p 44
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 717 718 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003481-Letvin1">[43]</xref>
###xml 887 888 887 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 420 423 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 534 539 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 943 948 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In summary, the results described above indicate a previously overlooked aspect of protective immunity against HIV-1, the selective protection of CD4+ T cells that secrete anti-viral CCR5 ligands during the primary immune response. At this point, our studies are limited to a model system in which naive CD4+ T cells are co-cultured with MDDC and an antigen to elicit a primary immune response. Our studies suggest that HIV specific CD4+ T cells that secrete anti-viral CCL5 ligands should be selectively protected during the primary HIV-1 infection and enter the memory pool. It is also possible that the relative survival of these cells is a determining factor in the relationship between the magnitude of early CD4+ T cell depletion and clinical outcome in SHIV vaccination models [43]. Most important, these conclusions suggest that the design immunogens which selectively elicit CD4+ T cell responses capable of "self-protection" against HIV-1 is a potential new strategy in the quest for an AIDS vaccine.
###end p 44
###begin p 45
We thank Dr. Robert C. Gallo for his generous and continuous support of this project and members of the Lewis and DeVico laboratories who have provided technical expertise for various aspects of this work. We also thank our many colleagues at the IHV for stimulating discussions.
###end p 45
###begin title 46
References
###end title 46
###begin article-title 47
###xml 67 70 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.
###end article-title 47
###begin article-title 48
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Control of HIV-1 infection by soluble factors of the immune response.
###end article-title 48
###begin article-title 49
###xml 8 13 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines.
###end article-title 49
###begin article-title 50
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
C-C chemokines, pivotal in protection against HIV type 1 infection.
###end article-title 50
###begin article-title 51
###xml 51 54 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 95 98 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Protective role of beta-chemokines associated with HIV-specific Th responses against perinatal HIV transmission.
###end article-title 51
###begin article-title 52
###xml 46 49 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.
###end article-title 52
###begin article-title 53
###xml 124 129 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection.
###end article-title 53
###begin article-title 54
###xml 102 107 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.
###end article-title 54
###begin article-title 55
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.
###end article-title 55
###begin article-title 56
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.
###end article-title 56
###begin article-title 57
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.
###end article-title 57
###begin article-title 58
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infectability of CD4+ lymphocytes with relation to beta-chemokines and the CCR5 coreceptor.
###end article-title 58
###begin article-title 59
###xml 83 118 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression.
###end article-title 59
###begin article-title 60
###xml 69 75 <span type="species:ncbi:9606">humans</span>
Perforin-low memory CD8+ cells are the predominant T cells in normal humans that synthesize the beta -chemokine macrophage inflammatory protein-1beta.
###end article-title 60
###begin article-title 61
Recall antigen activation induces prompt release of CCR5 ligands from PBMC: implication in memory responses and immunization.
###end article-title 61
###begin article-title 62
###xml 15 21 <span type="species:ncbi:9606">humans</span>
Vaccination in humans generates broad T cell cytokine responses.
###end article-title 62
###begin article-title 63
###xml 54 57 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation.
###end article-title 63
###begin article-title 64
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses.
###end article-title 64
###begin article-title 65
###xml 53 73 <span type="species:ncbi:520">Bordetella pertussis</span>
###xml 83 88 <span type="species:ncbi:9606">human</span>
Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway.
###end article-title 65
###begin article-title 66
###xml 51 56 <span type="species:ncbi:9606">human</span>
Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.
###end article-title 66
###begin article-title 67
###xml 0 21 <span type="species:ncbi:747">Pasteurella multocida</span>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 65 71 <span type="species:ncbi:10090">murine</span>
Pasteurella multocida toxin activates human monocyte-derived and murine bone marrow-derived dendritic cells in vitro but suppresses antibody production in vivo.
###end article-title 67
###begin article-title 68
###xml 20 55 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.
###end article-title 68
###begin article-title 69
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Naive and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implicatip6s for transmission and pathogenesis.
###end article-title 69
###begin article-title 70
###xml 50 53 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
CD8 naive T cell counts decrease progressively in HIV-infected adults.
###end article-title 70
###begin article-title 71
Superantigen stimulation reveals the contribution of Lck to negative regulation of T cell activation.
###end article-title 71
###begin article-title 72
Bacterial superantigens bypass Lck-dependent T cell receptor signaling by activating a Galpha11-dependent, PLC-beta-mediated pathway.
###end article-title 72
###begin article-title 73
Plasticity of T cell memory responses to viruses.
###end article-title 73
###begin article-title 74
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
T cell dynamics in HIV-1 infection.
###end article-title 74
###begin article-title 75
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Dynamics of fine T-cell subsets during HIV disease and after thymic ablation by mediastinal irradiation.
###end article-title 75
###begin article-title 76
###xml 93 128 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.
###end article-title 76
###begin article-title 77
###xml 32 35 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Biology of CCR5 and its role in HIV infection and treatment.
###end article-title 77
###begin article-title 78
Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.
###end article-title 78
###begin article-title 79
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 27 30 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV preferentially infects HIV-specific CD4+ T cells.
###end article-title 79
###begin article-title 80
###xml 81 84 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection.
###end article-title 80
###begin article-title 81
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.
###end article-title 81
###begin article-title 82
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
###end article-title 82
###begin article-title 83
###xml 90 95 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
###end article-title 83
###begin article-title 84
###xml 82 87 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
###end article-title 84
###begin article-title 85
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
###end article-title 85
###begin article-title 86
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
###end article-title 86
###begin article-title 87
###xml 90 125 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.
###end article-title 87
###begin article-title 88
###xml 57 92 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
###end article-title 88
###begin article-title 89
###xml 65 68 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.
###end article-title 89
###begin p 90
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 90
###begin p 91
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 103 108 <span type="species:ncbi:9606">Human</span>
Funding: The work was supported by NIH grants to GKL AND AD and intramural funds from the Institute of Human Virology. The funders had no role in study design, data collection analysis, decision to publish, or preparation of the manuscript.
###end p 91

